Korea Investment Corp
EDIT icon

Korea Investment Corp’s Editas Medicine EDIT Stock Holding History

Korea Investment Corp’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-52,600
Closed -$1.67M – 675
2018
Q3 		$1.67M Sell
52,600
-8,700
-14% -$281K 0.01% 536
2018
Q2 		$2.2M Buy
+61,300
New +$2.17M 0.01% 589

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Korea Investment Corp's EDIT Position: Q4 2018 in Review

Korea Investment Corp sold out of Editas Medicine (EDIT) in Q4 2018, closing a stake of 52,600 shares — an estimated $1.67M sold.

Korea Investment Corp first reported a position in EDIT in Q2 2018 and held it in 2 quarters. The position peaked at $2.2M in Q2 2018. 194 funds tracked by Wall St. Rank hold EDIT as of Q4 2018.

  • Korea Investment Corp reported no remaining Editas Medicine position as of Q4 2018 after selling out during the quarter.
  • Korea Investment Corp sold 52,600 Editas Medicine shares in Q4 2018, an estimated $1.67M.
  • Korea Investment Corp first reported a position in Editas Medicine in Q2 2018 and held it in 2 quarters.
  • Korea Investment Corp's Editas Medicine position peaked at $2.2M in Q2 2018.
  • 194 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2018.

Based on Korea Investment Corp's 13F filing for Q4 2018, filed 13 Feb 2019.